Toxoplasma gondii infection: novel emerging therapeutic targets

J Müller, A Hemphill - Expert opinion on therapeutic targets, 2023 - Taylor & Francis
Introduction Toxoplasmosis constitutes a challenge for public health, animal production, and
welfare. So far, only a limited panel of drugs has been marketed for clinical applications. In …

Treatment of toxoplasmosis and neosporosis in farm ruminants: state of knowledge and future trends

R Sánchez-Sánchez, P Vázquez, I Ferre… - Current topics in …, 2018 - ingentaconnect.com
Toxoplasmosis and neosporosis are closely related protozoan diseases that lead to
important economic impacts in farm ruminants. Toxoplasma gondii infection mainly causes …

[图书][B] Neosporosis in animals

JP Dubey, A Hemphill, R Calero-Bernal, G Schares - 2017 - taylorfrancis.com
Key features: Written by the scientist who named this parasite and was the first to set up
proper diagnostic techniques Serves as the first ever book to provide information on the …

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal …

RSR Vidadala, KL Rivas, KK Ojo… - Journal of medicinal …, 2016 - ACS Publications
New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by
the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent …

Unpacking the Pathogen Box—an open source tool for fighting neglected tropical disease

CGL Veale - ChemMedChem, 2019 - Wiley Online Library
Abstract The Pathogen Box is a 400‐strong collection of drug‐like compounds, selected for
their potential against several of the world's most important neglected tropical diseases …

In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum

P Winzer, J Müller, A Aguado-Martínez… - Antimicrobial agents …, 2015 - Am Soc Microbiol
We report on the in vitro effects of the bumped kinase inhibitor 1294 (BKI-1294) in cultures of
virulent Neospora caninum isolates Nc-Liverpool (Nc-Liv) and Nc-Spain7 and in two strains …

Drug target identification in protozoan parasites

J Müller, A Hemphill - Expert opinion on drug discovery, 2016 - Taylor & Francis
Introduction: Despite the fact that diseases caused by protozoan parasites represent serious
challenges for public health, animal production and welfare, only a limited panel of drugs …

Serology-based diagnostics for the control of bovine neosporosis

S Guido, F Katzer, I Nanjiani, E Milne, EA Innes - Trends in Parasitology, 2016 - cell.com
The protozoan Neospora caninum is a primary infectious cause of abortion in cattle that
causes significant economic losses worldwide. Because effective vaccines and licensed …

Extended-spectrum antiprotozoal bumped kinase inhibitors: a review

WC Van Voorhis, JS Doggett, M Parsons… - Experimental …, 2017 - Elsevier
Many life-cycle processes in parasites are regulated by protein phosphorylation. Hence,
disruption of essential protein kinase function has been explored for therapy of parasitic …

In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora …

D Imhof, N Anghel, P Winzer, V Balmer… - International Journal for …, 2021 - Elsevier
Bumped kinase inhibitors (BKIs) target the apicomplexan calcium-dependent protein kinase
1 (CDPK1). BKI-1748, a 5-aminopyrazole-4-carboxamide compound when added to …